ICU Trial in Critical Ill COVID-19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

31 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-08

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of our study is to observe the intensive care course in 30-50 COVID-19 patients with regard to cardiovascular risk factors and biomarkers.

The primary objective of this study is to investigate the cardiovascular risk and its impact on cardiovascular complications in COVID-19 patients in intensive care units.

This study is designed to investigate correlations and to investigate factors influencing the course of the new viral disease COVID-19 in intensive care. Previous scientific findings are still rare due to the relevance of the disease, therefore this study is also explorative and not exclusively based on a hypothesis.

The cardiovascular risk will be assessed upon admission to the intensive care unit and subsequently the course of biomarkers (see below) will be analysed in a cohort study (no, low and high cardiovascular risk).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

NCT04948242

SARS-CoV2 Infection

UNKNOWN

CharacterisatiON of carDiac funCTion in Intensive Care Unit Survivors of Sepsis.

NCT05633290

Heart Failure Myocarditis Sepsis +1 more

UNKNOWN

Fluid Responsiveness Tests in Critically Ill Patients During Admission to the Intensive Care Unit

NCT06729268

Shock Circulatory Heart Failure Hypovolemia

COMPLETED

Outcomes of Patients With COVID-19 in the Intensive Care Unit

NCT04336345

Coronavirus Infections COVID-19 Viral Pneumonia Human Coronavirus

COMPLETED

COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality

NCT04390074

COVID-19 Critical Illness

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this prospective observational study the course of 30-50 intensive care patients of the University Hospital of Graz is analysed.

It is not possible to give an exact number of cases, because it is not possible to estimate exactly how many COVID-19 patients will be admitted to the listed intensive care units in Graz. Recruitment will start when approved from the ethical board and end in June, 2020.

Inclusion criteria

* Admission on an isolation unit - intensive care unit of the University Clinic of Graz
* Detection of a SARS - CoV-2 infection by PCR (tracheal or pharyngeal secretion) or CT examination (with consecutive PCR confirmation)
* male and female sex
* subordinated declaration of consent if possible\*
* respiratory insufficiency with indication for non-invasive or invasive ventilation during admission to an intensive care unit

Informed consent

Since the study patients are intensive care patients, it may happen that the informed consent cannot be obtained at the time of admission to the intensive care unit (e.g.: patient is not able to give consent due to mechanical ventilation), in this case the informed consent will be obtained at a later time (e.g.: at the latest upon discharge from the intensive care unit/hospital.

(\* In exceptional cases it may happen that patients cannot sign a declaration of consent at admission as well as at discharge from the intensive care unit (e.g.: during the stay continuous mechanical ventilation and death at the intensive care unit).

Study related measures

In addition to the standardized routine laboratory (daily, in the morning approx. 05.00 o'clock), a lipid profile (LDL cholesterol, triglycerides, Lpa, HDL cholesterol, total cholesterol) is taken once upon admission to the intensive care unit in order to determine the cardiovascular risk upon admission to the intensive care unit. This lipid profile is taken with the aid of a vacuette (9 ml corresponds to approx. 2 teaspoons of whole blood).

Study related patient questionnaire for the determination of cardiovascular risk

The patient questionnaire should be filled out by interviewing the patients at the time of admission to the intensive care unit. If the condition of the patients does not allow this, the information in the questionnaire should be carried out by a member of the study staff by researching the patient's medical history (e.g. doctor's letters, electronic data acquisition, etc.). The questionnaire is used to assess the cardiovascular risk (contains medication, past medical history).

Non-study-related measures (standardised routine analyses in an intensive care unit)

To determine the cardiovascular risk:

See Patient Questionnaire, Lipid Status, HbA1c

For follow-up (daily routine laboratory checks):

Blood count, coagulation, liver and kidney counts, triglycerides, biomarkers (CK, CK-MB, TropT, NTproBNP, CRP, PCT, IL-6, D-dimer, LDH, myoglobin).

Other parameters and therapies that are considered in the evaluation or that are used to create the data set:

Fluid introduction, fluid discharge, balance, prone positioning, non-invasive ventilation (PEEP, fiO2), invasive ventilation (ventilation mode, PEEP, Pinsp, fiO2, AF), respiration (respiratory rate, fiO2, SpO2, paO2, pCO2, etCO2), circulation parameters (RR syst, RR dia, MAP, HF, ECG (rhythm, Qtc)), extracorporeal organ support procedures, mortality, med. complications, entire drug therapy (e.g: norepinephrine (incl. dose), levosimendan (incl. dose), vasopressin (incl. dose), cortisone (incl. dose), dobutamine (incl. dose), supportive therapy (zinc, vitamin C, selenium), antifungal and antibiotic therapy, hydroxychloroquine, lopinavir, remdesivir, favipiravir, tocilizumab.

Anonymisation of patients

After enrolment in the study, the patient data is encoded/pseudo-anonymised, i.e. patients are identified with a consecutive ID number (neither name, initials nor laboratory requirement number are recorded). To find out the previous illnesses of intensive care patients it is necessary to create a list of patient names and the corresponding ID numbers for pseudonymisation. This list remains with the investigator.

Use of clinical data For the statistical analysis, clinical data in pseudo-anonymised/encoded form are used, e.g. diagnosis, concomitant diseases, long-term medication, intensive care therapy, medication, smoking, age, sex.

Should further questions arise during the study regarding this patient collective, the collected data would be used for further evaluations.

Centre/intensive care units The test centre is the LKH Univ.Klinikum Graz, Auenbruggerplatz 5, A-8036 Graz. Patients are admitted to the SARS - CoV-2 (COVID-19) isolation unit intensive care units of the LKH University Hospital Graz.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Risk Factor, Cardiovascular Covid19 Critical Illness Course Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No cardiovascular risk

If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).

Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)

Intervention Type DIAGNOSTIC_TEST

Factorial

low cardiovascular risk

Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)

Intervention Type DIAGNOSTIC_TEST

Factorial

high cardiovascular risk

Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)

Intervention Type DIAGNOSTIC_TEST

Factorial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)

Factorial

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluid management (fluid input, fluid output), prone positioning, ventilation, respiration, circulation parameters, extracorporeal organ support procedures, mortality, MACE, entire drug therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admission on an isolation unit - intensive care unit of the LKH Univ. Klinikum Graz
* Detection of a SARS - CoV-2 infection by PCR (tracheal or pharyngeal secretion) or CT examination (with subsequent PCR detection)
* male and female sex
* subordinated declaration of consent if possible if applicable
* respiratory insufficiency with indication for non-invasive or invasive ventilation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No